Analysed ADLAI NORTYE LTD-ADR (ANL:NASDAQ) News Sources
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
12-02-2026
yahoo.com
Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair
30-01-2026
yahoo.com
Investors Calmed by Trump's Choice of Warsh as Fed Chair, Look Ahead to Inflation Data
30-01-2026
yahoo.com
Individual investors are Adlai Nortye Ltd.'s (NASDAQ:ANL) biggest owners and were rewarded after market cap rose by US$65m last week
28-01-2026
yahoo.com
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
29-12-2025
yahoo.com
What is the current price of ADLAI NORTYE LTD-ADR (ANL:NASDAQ)?
The current price of ADLAI NORTYE LTD-ADR (ANL:NASDAQ) is $12.08.
ADLAI NORTYE LTD-ADR (ANL:NASDAQ) absolute price change since previous trading day?
The absolute price change of ADLAI NORTYE LTD-ADR (ANL:NASDAQ) since the previous trading day is $0.92.
ADLAI NORTYE LTD-ADR (ANL:NASDAQ) percentage price change since previous trading day?
The percentage price change of ADLAI NORTYE LTD-ADR (ANL:NASDAQ) since the previous trading day is 8.2437%.
What is the most recent average sentiment score for ADLAI NORTYE LTD-ADR (ANL:NASDAQ)?
The most recent average sentiment score for ADLAI NORTYE LTD-ADR (ANL:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for ADLAI NORTYE LTD-ADR (ANL:NASDAQ)?
The most recent sentiment for ADLAI NORTYE LTD-ADR (ANL:NASDAQ) is .
SEC-8K** Filing Available For ADLAI NORTYE LTD-ADR (ANL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.